23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection [Ocrevus Zunovo]
- RxCUI
- 2693465
- RxNorm name
- 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection [Ocrevus Zunovo]
- Display name
- 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection [Ocrevus Zunovo]
- Full name
- 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection [Ocrevus Zunovo]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:16
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761371 | Ocrevus Zunovo | ocrelizumab and hyaluronidase-ocsq | 351(a) | Rx | 2026-08-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ocrevus Zunovo | OCRELIZUMAB AND HYALURONIDASE | Genentech, Inc. | b216af61-99d0-42a3-afc2-b5bf86df1ec0 | 2026-08-17 | Warnings, Adverse reactions | 2693465 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| b216af61-99d0-42a3-afc2-b5bf86df1ec0 | Ocrevus Zunovo 920 MG / 23,000 UNT in 23 ML Injection [PSN] · 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection [Ocrevus Zunovo] [SBD] · Ocrevus Zunovo (ocrelizumab-hyaluronidase-ocsq 920 MG / 23,000 UNT) per 23 ML Injection [SY] | 3 | 9 | These highlights do not include all the information needed to use OCREVUS ZUNOVO safely and effectively. See full prescribing information for OCREVUS ZUNOVO. OCREVUS ZUNOVO ® (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use Initial U.S. Approval: 2024 | 20260427 |